Brepocitinib, a novel oral TYK2/JAK1 inhibitor, demonstrated significant clinical efficacy in the phase 3 VALOR trial for dermatomyositis, achieving superior improvement scores, higher remission rates and meaningful reductions in corticosteroid use compared with placebo. Rapid improvements in itch, muscle strength and quality of life were observed, with a favorable safety profile and no increase in major adverse events such as thrombosis or malignancy. These findings mark a major advancement in targeted therapy for this difficult-to-treat autoimmune disease.
DERMATOLOGYMICROBIOLOGY ADVANCEMENTSTRIALS < class="penci-entry-title entry-title grid-title penci_grid_title">Brepocitinib โa major move forwardโ as first targeted therapy for dermatomyositis: VALOR